Human medicines European public assessment report (EPAR): Orkambi, lumacaftor,ivacaftor, Date of authorisation: 19/11/2015, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Briviact (in Italy: Nubriveo), brivaracetam, Date of authorisation: 13/01/2016, Revision: 23, Status: Authorised

Paediatric investigation plans: submitting documents

Human medicines European public assessment report (EPAR): Entyvio, vedolizumab, Date of authorisation: 22/05/2014, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Evrenzo, roxadustat, Date of authorisation: 18/08/2021, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Veoza, fezolinetant, Date of authorisation: 07/12/2023, Revision: 2, Status: Authorised

EMA traineeship programme informative session, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 23 April 2024, 10:00 (CEST) to 23 April 2024, 11:00 (CEST)

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Zoonotic Influenza Vaccine Seqirus, Zoonotic influenza vaccine (H5N8) (surface antigen, inactivated, adjuvanted), Date of authorisation: 09/10/2023, Revision: 1, Status: Authorised

Clinical Trials Information System: training and support